Mora Johanna R, Obenauer-Kutner Linda, Vimal Patel Vimal
Bristol-Myers Squibb, Route 206 & Province Line Rd, Princeton, NJ, USA.
Bioanalysis. 2010 Oct;2(10):1711-5. doi: 10.4155/bio.10.122.
In many areas of drug discovery and development, scientists are in a constant search for methods and platforms to reduce assay time and cost. The Gyrolab™ microfluidics platform that we describe here promises to deliver faster ligand-binding assays with lower reagent and sample consumption, while maintaining good accuracy and precision. Due to its limited track record, we evaluated its performance on assays currently used to support pharmacokinetic and immunogenicity studies, and detection of host cell protein impurities in samples from biotechnology processes. This article summarizes our preliminary conclusions about the utility of the Gyrolab microfluidics platform from Gyros AB.
在药物研发的许多领域,科学家们一直在不断寻找能够减少检测时间和成本的方法及平台。我们在此描述的Gyrolab™微流控平台有望实现更快的配体结合检测,同时降低试剂和样品消耗,且能保持良好的准确性和精密度。鉴于其应用记录有限,我们评估了它在目前用于支持药代动力学和免疫原性研究以及检测生物技术过程样品中宿主细胞蛋白杂质的检测方法上的性能。本文总结了我们对Gyros AB公司的Gyrolab微流控平台实用性的初步结论。